- cafead Apr 18, 2021 at 12:22: AM
via Just as pharma watchers were bracing themselves for the brunt of renewed antitrust scrutiny around large biopharma transactions, AstraZeneca’s mega-acquisition of Alexion Pharma sailed through the much-dreaded review unscathed.
In an anticlimactic announcement Friday, AZ said the U.S. Federal Trade Commission has cleared the $39 billion deal first unveiled in December.
article source
In an anticlimactic announcement Friday, AZ said the U.S. Federal Trade Commission has cleared the $39 billion deal first unveiled in December.
article source